Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant

NCT04836390 · clinicaltrials.gov ↗
PHASE2
Phase
ENROLLING_BY_INVITATION
Status
30
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Michael Pulsipher

Collaborators